Text Size

Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Merck Frosst Canada Ltd.
Information provided by:
Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier:
NCT01183481
First received: August 4, 2010
Last updated: December 15, 2010
Last verified: December 2010
History of Changes
  Purpose

The primary objective of this pilot study is to examine the efficacy of Aprepitant given in combination with Granisetron for the prevention of delayed-phase RINV in 84 patients receiving a single 8Gy of moderately emetogenic palliative RT in the RRRP at Sunnybrook Odette Cancer Centre for painful bony metastases from any primary solid tumor. Patients will be given a single dose of Granisetron 2 mg orally and Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.. Secondary objectives include determining the complete RINV prophylaxis rate (acute and delayed phases), the partial emesis control rate, the safety of the combined regime, QOL issues, the time to the first emetic event and the time to the first use of rescue medication .


Condition Intervention Phase
Nausea
Vomiting
 Drug: Aprepitant
 Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Sunnybrook Health Sciences Centre:

Primary Outcome Measures:
  • The proportion of patients experiencing no vomiting and no nausea, without use of any rescue antiemetic medication(s), from days 2-10 following the radiation therapy (delayed RINV). [ Time Frame: Days 2-10 following radiotherapy ] [ Designated as safety issue: No ]
    Measurements will be taken daily within this time with patient self-report nausea diaries.


Secondary Outcome Measures:
  • The complete RINV prophylaxis rate (acute and delayed phases), the partial emesis control rate, the safety of the combined regime, QOL issues, the time to the first emetic event and use of rescue medication . [ Time Frame: From day of radiotherapy to 10 days following radiotherapy ] [ Designated as safety issue: No ]
    Data will be measured by research staff at baseline and patient self-report nausea diaries will be taken on each day within this time frame.


Estimated Enrollment: 84
Study Start Date: December 2010
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aprepitant and Granisetron
Patients will be given a single dose of Granisetron 2 mg orally and Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.
 Drug: Aprepitant
Patients will be given a single dose of Granisetron 2 mg orally and Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with bone metastases from any primary solid tumor site scheduled to receive a single 8 Gy fraction of palliative radiotherapy considered to be moderately emetogenic (an area of at least 80 cm2 in the anterior/posterior direction and located between the level of upper border of T11 and the lower border of L3) in the RRRP at Sunnybrook Odette Cancer Centre will be considered eligible.

Exclusion Criteria:

  • Exclusion criteria include having nausea or vomiting 24hrs prior to radiation
  • Having received or being scheduled to receive cranial radiation, moderately or highly emetogenic cytotoxic therapy 7 days prior to, during, or after radiation, receiving corticosteroids (except inhaled or topical), 5HT3 receptor antagonists or NK-1 antagonists or other antiemetic medication, being allergic to study medications, having a KPS<40, being pregnant or of childbearing potential and not using contraceptive measures.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01183481

Locations
Canada, Ontario
Odette Cancer Centre, Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N3M5
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Merck Frosst Canada Ltd.
Investigators
Principal Investigator: Edward Chow, MBBS PhD FRCPC Odette Cancer Centre, Sunnybrook Health Sciences Centre
  More Information

No publications provided

Responsible Party: Dr Edward Chow, Odette Cancer Centre, Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier: NCT01183481     History of Changes
Other Study ID Numbers: RINV Prophylaxis
Study First Received: August 4, 2010
Last Updated: December 15, 2010
Health Authority: Canada: Health Canada

Keywords provided by Sunnybrook Health Sciences Centre:
nausea
vomiting
antiemetics
radiotherapy
Radiation-induced nausea and vomiting

Additional relevant MeSH terms:
Nausea
Vomiting
Signs and Symptoms, Digestive
Signs and Symptoms
Granisetron
Aprepitant
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Gastrointestinal Agents
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on October 17, 2012